Drug Trial Radar · NCT06125197
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
22
Planned (sponsor's estimate)
Start
Jul 23, 2024
Primary completion
Jan 30, 2026
Study completion May 30, 2026
Sponsor
- Lead sponsor
- TILT Biotherapeutics Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Nov 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.
Conditions
- Lung Cancer
Interventions
TILT-123Biological
Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
KEYTRUDA®Biological
pembrolizumab, a monoclonal antibody binding PD-1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation PhaseTime frame: Day 1 to Day 85
- Incidence of Adverse EventsTime frame: Day 1 to Day 85
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hoag Memorial Hospital Presbyterian
Newport Beach, California
UCLA Jonsson Comprehensive Cancer Center
Santa Monica, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.